Gastric Cancer Clinical Trial
Official title:
Real World Study of Immune Checkpoint Inhibitors for Advanced Gastric Cancer
Gastric cancer ranks as the fifth most common and the third most common cause of cancer
deaths in the world. In spite of the progresses made in the diagnosis and treatment of
gastric cancer in the past decades, the prognosis is still unsatisfied mainly due to
recurrence and distant metastasis. Surgical treatment is the first choice for the treatment
of early gastric cancer, but it is prone to recurrence and metastasis after surgery. There
are relatively few chemotherapy drugs for gastric cancer. Studies have shown that about 13%
of gastric cancers have HER2 gene amplification, and there are no other known driver gene
other than HER-2. At present, the targeted therapeutic drugs approved for gastric cancer in
China are only trastuzumab and apatinib.
Immune checkpoint inhibitors, including PD-1 inhibitors, PD-L1 inhibitors and CTLA-4
inhibitors, have achieved significant therapeutic effects in a variety of tumors and are
expected to alter the current state of treatment of tumors. In gastric cancer, the
KEYNOTE-012 study demonstated the efficacy of Pembrolizumab in patients with PD-L1 positive
advanced gastric cancer. The study showed that 53% of patients had tumor retraction, and 22%
achieved partial imaging remission with a median duration of 40 weeks. At the same time,
Pembrolizumab is also less toxic than standard second-line chemotherapy. However, Are the
Immune checkpoint inhibitors should be used as single-drug or in combination with
chemotherapy? Are the Immune checkpoint inhibitors should be used in the first-line or in the
back-line? And which is the best combination therapy? For these issues, there is no
conclusion yet.
This observational study included all patients with gastric cancer who used Immune checkpoint
inhibitors in clinical practice, regardless of treatment lines and combination with different
chemotherapy. Through follow-up observations, the aim of this study is to analyze the
efficacy of Immune checkpoint inhibitors for gastric cancer in the real world, and to explore
the differences in the efficacy of Immune checkpoint inhibitors in different stages of
treatment, as well as the efficacy of different chemotherapy combinations, so as to provide
clinical evidence for the use of immunotherapy for advanced gastric cancer.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05551416 -
The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer
|
||
| Completed |
NCT05518929 -
Hypoxia During Gastroenterological Endoscope Procedures Sedated With Ciprofol In Overweight Or Obesity Patients
|
Phase 4 | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03219593 -
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT05489211 -
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
|
Phase 2 | |
| Recruiting |
NCT05536102 -
The Effectiveness and Safety of XELOX and Tislelizumab + PLD for Resectable Gastric Cancer (LidingStudy)
|
Phase 2 | |
| Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06010862 -
Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Active, not recruiting |
NCT04082364 -
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
|
Phase 2/Phase 3 | |
| Withdrawn |
NCT03766607 -
Trastuzumab Beyond Progression in HER2 Positive Metastatic Gastric Cancer
|
Phase 2 | |
| Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
| Completed |
NCT01924533 -
Efficacy and Safety Study of Olaparib in Combination With Paclitaxel to Treat Advanced Gastric Cancer.
|
Phase 3 | |
| Terminated |
NCT01641939 -
A Study of Trastuzumab Emtansine Versus Taxane in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05107674 -
A Study of NX-1607 in Adults With Advanced Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT04908813 -
Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT04249739 -
Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 Positive
|
Phase 2 | |
| Recruiting |
NCT05514158 -
To Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Disitamab Vedotin Combined With RC98 in the Treatment of Subjects With HER2-expressing Locally Advanced or Metastatic Gastric Cancer (Including AEG)
|
Phase 1 | |
| Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03175224 -
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
|
Phase 2 |